What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.…
What is Kyverna Therapeutics, Inc.'s P/E and P/B ratio?
Kyverna Therapeutics, Inc. has a P/E ratio of -2.0 and a P/B ratio of 2.14.
What is Kyverna Therapeutics, Inc.'s debt-to-equity ratio?
Kyverna Therapeutics, Inc. has a debt-to-equity ratio of 0.20.
How much does Kyverna Therapeutics, Inc. owe compared with what it owns?
Kyverna Therapeutics, Inc. owes $0.25 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Kyverna Therapeutics, Inc.'s Positivity rank?
Kyverna Therapeutics, Inc. is ranked #3,045 of 6,774 companies globally and #1,177 of 4,000 in United States on PositoAI, with a Positivity Score of 20,912.
Does Kyverna Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Kyverna Therapeutics, Inc..
Where can I read the latest news about Kyverna Therapeutics, Inc.?
Recent headlines about Kyverna Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Kyverna Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Kyverna Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.